TABLE 2

Omeprazole plasma concentrations coadministered with placebo or clopidogrel in studies 1, 2, and 3 (see Materials and Methods)

Data are arithmetic means (S.D.).

TreatmentDay −5 T2aDay 1, T2bDay 4, T12Day 5, T2
ng/ml
Study 1
    Omeprazole + clopidogrel (n = 64)1220 (1080)2790 (1380)2890 (1330)
    Omeprazole + placebo (n = 5)1490 (809)2290 (2080)3210 (2120)
    Ratioc (P valued)1.22 (P = 0.449)0.90 (P = 0.619)
Study 2e
    Omeprazole + clopidogrel (n = 66)768 (977)388 (615)319 (304)997 (1140)
    Omeprazole + placebo (n = 6)337 (274)326 (444)274 (235)1640 (1170)
Ratioc (P valued)1.19 (P = 0.812)1.16 (P = 0.727)0.61 (P = 0.189)
Study 3
    Omeprazole + clopidogrel (n = 66)1320 (966)2290 (1080)2460 (1020)
    Omeprazole + placebo (n = 6)1740 (1040)2650 (1350)3080 (763)
Ratioc (P valued)0.86 (P = 0.449)0.80 (P = 0.152)
  • a Omeprazole alone, first day of administration.

  • b First day of clopidogrel administration, coadministered with omeprazole.

  • c Ratio of arithmetic means.

  • d Testing the equality of means between two treatments.

  • e In study 2, concentrations reported at 2 h after dose of omeprazole were lower than those reported for omeprazole administered in a fasted state (studies 1 and 3). This is probably due to the administration in a nonfasted state, because dinner was provided commencing 2 h before omeprazole administration, and food appears to increase tmax (up to 4 h) and decrease Cmax. In this study, variability observed between day 1 and day 5 is likely to stem from food effect.